Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 26;8:1581–1588. doi: 10.2147/OTT.S84994

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Guo et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Relationship between clinical variables and PFS.

Notes: (A) There was no significant difference between male group and female group for PFS in patients with mRCC (P>0.05). (B) Both groups with age <65 years and age ≥65 years had no difference in PFS (P>0.05). (C) PFS for patients with ECOG PS 0/1 was better than those cases with PS 2 (16.1 months vs 2.9 months, P<0.05; 12.3 months vs 2.9 months, P<0.05). (D) Metastatic sites had no obvious correlation with PFS in patients with mRCC (P>0.05). (E) Patients who undergo nephrectomy + immunotherapy or immunotherapy alone had a longer lifetime than those cases who only undergo surgery or untreated (12.4 months vs 5.3 months, P<0.05; 12.4 months vs 3.1 months, P<0.05; 12.3 months vs 5.3 months, P<0.05; 12.3 months vs 3.1 months, P<0.05).

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; mRCC, metastatic renal cell cancer; PFS, progression-free survival.

Relationship between clinical variables and PFS.

Notes: (A) There was no significant difference between male group and female group for PFS in patients with mRCC (P>0.05). (B) Both groups with age <65 years and age ≥65 years had no difference in PFS (P>0.05). (C) PFS for patients with ECOG PS 0/1 was better than those cases with PS 2 (16.1 months vs 2.9 months, P<0.05; 12.3 months vs 2.9 months, P<0.05). (D) Metastatic sites had no obvious correlation with PFS in patients with mRCC (P>0.05). (E) Patients who undergo nephrectomy + immunotherapy or immunotherapy alone had a longer lifetime than those cases who only undergo surgery or untreated (12.4 months vs 5.3 months, P<0.05; 12.4 months vs 3.1 months, P<0.05; 12.3 months vs 5.3 months, P<0.05; 12.3 months vs 3.1 months, P<0.05).

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; mRCC, metastatic renal cell cancer; PFS, progression-free survival.